NCT06254560View on ClinicalTrials.gov

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Severe Aplastic AnemiaPlatelet Transfusion Refractoriness
Interventions
DRUG

Rituximab

Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER